We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
10
Feb 2026
In a major leap for cancer care at the University of Missouri, the School of Medicine and MU Health Care have launched their first clinical trial using a leading-edge therapy manufactured on campus at the university's research reactor.
10
Feb 2026
Age-related memory decline and neurodegenerative diseases like Alzheimer's are often thought of as irreversible.
10
Feb 2026
Inherited hyperbilirubinemia, encompassing Gilbert syndrome, Crigler-Najjar syndrome, Dubin-Johnson syndrome, and Rotor syndrome, represents a spectrum of disorders rooted in genetic defects affecting bilirubin metabolism and transport.
10
Feb 2026
A new breakthrough study led by researchers at the University of Minnesota Twin Cities could explain why patients with the same genetic sickle cell mutation experience different levels of pain, organ damage and response to treatment.